nodes	percent_of_prediction	percent_of_DWPC	metapath
Almotriptan—MAOA—attention deficit hyperactivity disorder	0.437	0.512	CbGaD
Almotriptan—HTR1B—attention deficit hyperactivity disorder	0.417	0.488	CbGaD
Almotriptan—MAOA—locus ceruleus—attention deficit hyperactivity disorder	0.00854	0.256	CbGeAlD
Almotriptan—HTR1B—forebrain—attention deficit hyperactivity disorder	0.00143	0.043	CbGeAlD
Almotriptan—HTR1D—forebrain—attention deficit hyperactivity disorder	0.00139	0.0416	CbGeAlD
Almotriptan—FMO3—nervous system—attention deficit hyperactivity disorder	0.00133	0.0398	CbGeAlD
Almotriptan—Naratriptan—MAOA—attention deficit hyperactivity disorder	0.0013	0.145	CrCbGaD
Almotriptan—FMO3—central nervous system—attention deficit hyperactivity disorder	0.00128	0.0383	CbGeAlD
Almotriptan—Naratriptan—HTR1B—attention deficit hyperactivity disorder	0.00124	0.138	CrCbGaD
Almotriptan—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.00121	0.0363	CbGeAlD
Almotriptan—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.00117	0.0352	CbGeAlD
Almotriptan—Rizatriptan—MAOA—attention deficit hyperactivity disorder	0.00108	0.12	CrCbGaD
Almotriptan—MAOA—forebrain—attention deficit hyperactivity disorder	0.00106	0.0317	CbGeAlD
Almotriptan—Rizatriptan—HTR1B—attention deficit hyperactivity disorder	0.00103	0.114	CrCbGaD
Almotriptan—FMO3—brain—attention deficit hyperactivity disorder	0.00101	0.0304	CbGeAlD
Almotriptan—Zolmitriptan—MAOA—attention deficit hyperactivity disorder	0.000986	0.11	CrCbGaD
Almotriptan—HTR1B—midbrain—attention deficit hyperactivity disorder	0.000947	0.0284	CbGeAlD
Almotriptan—Zolmitriptan—HTR1B—attention deficit hyperactivity disorder	0.000941	0.105	CrCbGaD
Almotriptan—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000917	0.0275	CbGeAlD
Almotriptan—MAOA—cardiovascular system—attention deficit hyperactivity disorder	0.000894	0.0268	CbGeAlD
Almotriptan—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000778	0.0233	CbGeAlD
Almotriptan—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000754	0.0226	CbGeAlD
Almotriptan—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000749	0.0225	CbGeAlD
Almotriptan—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000726	0.0217	CbGeAlD
Almotriptan—Sumatriptan—MAOA—attention deficit hyperactivity disorder	0.000719	0.0799	CrCbGaD
Almotriptan—MAOA—midbrain—attention deficit hyperactivity disorder	0.000698	0.0209	CbGeAlD
Almotriptan—Sumatriptan—HTR1B—attention deficit hyperactivity disorder	0.000687	0.0763	CrCbGaD
Almotriptan—CYP2E1—cardiovascular system—attention deficit hyperactivity disorder	0.000671	0.0201	CbGeAlD
Almotriptan—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000628	0.0188	CbGeAlD
Almotriptan—HTR1B—brain—attention deficit hyperactivity disorder	0.000595	0.0178	CbGeAlD
Almotriptan—HTR1D—brain—attention deficit hyperactivity disorder	0.000576	0.0173	CbGeAlD
Almotriptan—MAOA—nervous system—attention deficit hyperactivity disorder	0.000574	0.0172	CbGeAlD
Almotriptan—Eletriptan—HTR1B—attention deficit hyperactivity disorder	0.000556	0.0617	CrCbGaD
Almotriptan—MAOA—central nervous system—attention deficit hyperactivity disorder	0.000553	0.0166	CbGeAlD
Almotriptan—MAOA—cerebellum—attention deficit hyperactivity disorder	0.00054	0.0162	CbGeAlD
Almotriptan—Sumatriptan—DRD2—attention deficit hyperactivity disorder	0.000461	0.0512	CrCbGaD
Almotriptan—MAOA—brain—attention deficit hyperactivity disorder	0.000439	0.0131	CbGeAlD
Almotriptan—CYP2E1—nervous system—attention deficit hyperactivity disorder	0.000431	0.0129	CbGeAlD
Almotriptan—CYP2E1—central nervous system—attention deficit hyperactivity disorder	0.000415	0.0124	CbGeAlD
Almotriptan—CYP2E1—cerebellum—attention deficit hyperactivity disorder	0.000405	0.0121	CbGeAlD
Almotriptan—CYP2C8—brain—attention deficit hyperactivity disorder	0.000391	0.0117	CbGeAlD
Almotriptan—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000347	0.0104	CbGeAlD
Almotriptan—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000341	0.0102	CbGeAlD
Almotriptan—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000334	0.01	CbGeAlD
Almotriptan—CYP2E1—brain—attention deficit hyperactivity disorder	0.000329	0.00987	CbGeAlD
Almotriptan—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000328	0.00984	CbGeAlD
Almotriptan—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000321	0.00962	CbGeAlD
Almotriptan—CYP2D6—brain—attention deficit hyperactivity disorder	0.000261	0.00781	CbGeAlD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000224	0.00218	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00022	0.00213	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000216	0.00209	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000211	0.00205	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000211	0.00205	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000211	0.00205	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000211	0.00205	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000207	0.00201	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000196	0.0019	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000196	0.0019	CbGpPWpGaD
Almotriptan—CYP2E1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000192	0.00187	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000192	0.00187	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00019	0.00185	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000188	0.00183	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000188	0.00183	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000187	0.00182	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000186	0.00181	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000185	0.00179	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000183	0.00178	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000182	0.00177	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000182	0.00176	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000181	0.00176	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000179	0.00173	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000178	0.00173	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000177	0.00171	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000175	0.0017	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000174	0.00169	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000174	0.00169	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000173	0.00168	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000172	0.00167	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000171	0.00166	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00017	0.00165	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000169	0.00164	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000168	0.00163	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000168	0.00163	CbGpPWpGaD
Almotriptan—MAOA—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000168	0.00163	CbGpPWpGaD
Almotriptan—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000166	0.00161	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000165	0.0016	CbGpPWpGaD
Almotriptan—FMO3—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000163	0.00158	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000162	0.00157	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000162	0.00157	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00016	0.00155	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000156	0.00152	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000156	0.00152	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000153	0.00149	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000151	0.00147	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00015	0.00146	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000149	0.00144	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000149	0.00144	CbGpPWpGaD
Almotriptan—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000148	0.00144	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000148	0.00144	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000147	0.00143	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000147	0.00143	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000146	0.00142	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000146	0.00141	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000144	0.0014	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000144	0.00139	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000143	0.00139	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000137	0.00133	CbGpPWpGaD
Almotriptan—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000136	0.00133	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000134	0.0013	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000134	0.0013	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000128	0.00124	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000122	0.00118	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000119	0.00116	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000119	0.00116	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000119	0.00116	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000117	0.00113	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000116	0.00113	CbGpPWpGaD
Almotriptan—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000116	0.00112	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000115	0.00112	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000114	0.00111	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000113	0.0011	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000113	0.0011	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000112	0.00109	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000112	0.00109	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000111	0.00108	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000111	0.00107	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00011	0.00106	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00011	0.00106	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000108	0.00105	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000108	0.00105	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000106	0.00103	CbGpPWpGaD
Almotriptan—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000106	0.00103	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000104	0.00101	CbGpPWpGaD
Almotriptan—CYP2E1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000103	0.000999	CbGpPWpGaD
Almotriptan—CYP2E1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000102	0.000992	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000102	0.000991	CbGpPWpGaD
Almotriptan—CYP2E1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000101	0.000985	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—TPH2—attention deficit hyperactivity disorder	9.91e-05	0.000962	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.91e-05	0.000962	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—DPYD—attention deficit hyperactivity disorder	9.75e-05	0.000946	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	9.74e-05	0.000946	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	9.58e-05	0.00093	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	9.54e-05	0.000926	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	9.38e-05	0.000911	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.06e-05	0.00088	CbGpPWpGaD
Almotriptan—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	8.92e-05	0.000866	CbGpPWpGaD
Almotriptan—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	8.89e-05	0.000864	CbGpPWpGaD
Almotriptan—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	8.83e-05	0.000857	CbGpPWpGaD
Almotriptan—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	8.77e-05	0.000852	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	8.27e-05	0.000803	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	8.1e-05	0.000787	CbGpPWpGaD
Almotriptan—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.94e-05	0.000771	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.92e-05	0.000769	CbGpPWpGaD
Almotriptan—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.88e-05	0.000765	CbGpPWpGaD
Almotriptan—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.83e-05	0.00076	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	7.78e-05	0.000755	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	7.62e-05	0.00074	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	7.62e-05	0.00074	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	7.61e-05	0.000739	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.54e-05	0.000732	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	7.51e-05	0.000729	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	7.45e-05	0.000723	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	7.36e-05	0.000714	CbGpPWpGaD
Almotriptan—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.3e-05	0.000709	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	7.3e-05	0.000709	CbGpPWpGaD
Almotriptan—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.25e-05	0.000704	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	7.23e-05	0.000702	CbGpPWpGaD
Almotriptan—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.2e-05	0.000699	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	7.15e-05	0.000694	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.86e-05	0.000666	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	6.72e-05	0.000653	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	6.58e-05	0.000639	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	6.57e-05	0.000638	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	6.54e-05	0.000635	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	6.51e-05	0.000632	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	6.4e-05	0.000622	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	6.4e-05	0.000621	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	6.4e-05	0.000621	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	6.38e-05	0.000619	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	6.32e-05	0.000614	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	6.28e-05	0.00061	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	6.27e-05	0.000609	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	6.27e-05	0.000608	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	6.19e-05	0.000601	CbGpPWpGaD
Almotriptan—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.19e-05	0.000601	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	6.15e-05	0.000597	CbGpPWpGaD
Almotriptan—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.14e-05	0.000596	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	6.11e-05	0.000593	CbGpPWpGaD
Almotriptan—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.1e-05	0.000592	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—COMT—attention deficit hyperactivity disorder	6e-05	0.000583	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.98e-05	0.00058	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—MAOA—attention deficit hyperactivity disorder	5.96e-05	0.000579	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.91e-05	0.000574	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.89e-05	0.000572	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.81e-05	0.000564	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.79e-05	0.000562	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.77e-05	0.00056	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.74e-05	0.000557	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.69e-05	0.000553	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.62e-05	0.000546	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	5.35e-05	0.000519	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	5.24e-05	0.000508	CbGpPWpGaD
Almotriptan—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.77e-05	0.000463	CbGpPWpGaD
Almotriptan—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.74e-05	0.00046	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—TPH2—attention deficit hyperactivity disorder	4.73e-05	0.00046	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.73e-05	0.00046	CbGpPWpGaD
Almotriptan—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.71e-05	0.000457	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—DPYD—attention deficit hyperactivity disorder	4.66e-05	0.000452	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.44e-05	0.000431	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.35e-05	0.000422	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.33e-05	0.00042	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.21e-05	0.000409	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.12e-05	0.0004	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.04e-05	0.000392	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.88e-05	0.000377	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.78e-05	0.000367	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.75e-05	0.000364	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.67e-05	0.000356	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.64e-05	0.000353	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.61e-05	0.00035	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.6e-05	0.00035	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.53e-05	0.000343	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.49e-05	0.000339	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.43e-05	0.000333	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.42e-05	0.000332	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.39e-05	0.000329	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.36e-05	0.000326	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.32e-05	0.000322	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.25e-05	0.000315	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.16e-05	0.000307	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.09e-05	0.0003	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.99e-05	0.00029	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—TPH2—attention deficit hyperactivity disorder	2.9e-05	0.000282	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.9e-05	0.000282	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—COMT—attention deficit hyperactivity disorder	2.87e-05	0.000278	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—DPYD—attention deficit hyperactivity disorder	2.86e-05	0.000277	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.66e-05	0.000258	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—EP300—attention deficit hyperactivity disorder	2.57e-05	0.00025	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.53e-05	0.000246	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	2.51e-05	0.000244	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.51e-05	0.000244	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	2.47e-05	0.00024	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.32e-05	0.000225	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.3e-05	0.000223	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	2.24e-05	0.000218	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.24e-05	0.000218	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.21e-05	0.000215	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.21e-05	0.000215	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	2.2e-05	0.000214	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.17e-05	0.00021	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.06e-05	0.0002	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.06e-05	0.0002	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.05e-05	0.000199	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.03e-05	0.000197	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.01e-05	0.000195	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.95e-05	0.00019	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.91e-05	0.000185	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.89e-05	0.000183	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.79e-05	0.000174	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—COMT—attention deficit hyperactivity disorder	1.76e-05	0.000171	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.75e-05	0.00017	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	1.75e-05	0.00017	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.75e-05	0.00017	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	1.72e-05	0.000167	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.71e-05	0.000166	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.65e-05	0.00016	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.6e-05	0.000155	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.57e-05	0.000152	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	1.52e-05	0.000148	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	1.51e-05	0.000147	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.46e-05	0.000142	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.4e-05	0.000136	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	1.36e-05	0.000132	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	1.35e-05	0.000131	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.35e-05	0.000131	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.35e-05	0.000131	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.33e-05	0.000129	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.33e-05	0.000129	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.31e-05	0.000127	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.25e-05	0.000121	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.24e-05	0.00012	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.23e-05	0.00012	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—EP300—attention deficit hyperactivity disorder	1.23e-05	0.000119	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.17e-05	0.000114	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.15e-05	0.000111	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.08e-05	0.000105	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	1.06e-05	0.000103	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	1.05e-05	0.000102	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.03e-05	9.96e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.02e-05	9.89e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	8.16e-06	7.93e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	8.11e-06	7.87e-05	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—EP300—attention deficit hyperactivity disorder	7.55e-06	7.33e-05	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	6.52e-06	6.33e-05	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	5.82e-06	5.65e-05	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	5.36e-06	5.2e-05	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	4.54e-06	4.4e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.5e-06	3.4e-05	CbGpPWpGaD
